Further elucidation of the differences in drug-induced outcomes for GNAQ and BRAF mutant uveal melanomas revealed that AKT, 4E-BP1, and MCL-1 were cooperatively regulated by the AZD8055/selumetinib combination only in BRAF mutant cells and not GNAQ cells (Figure 8A), suggesting these as candidate targets responsible for the distinct apoptotic outcomes observed. The gene discussed is BRAF; the disease is uveal melanoma.